Intrinsiqq
Bio-Rad Laboratories Inc. logo

Bio-Rad Laboratories Inc. Financials

BIO

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 19 available years
Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$2,591$2,582$2,567$2,671$2,795$2,923
Cost of Revenue$1,264$1,243$1,188$1,244$1,235$1,284
Gross Profit$1,329$1,340$1,379$1,427$1,567$1,638
General & Administrative$903$844$814$842$828$877
Research & Development$266$276$296$247$257$261
Provision for Doubtful Accounts-$1-$2-$1$1$2$1
Total Operating Expenses$2,653$2,535$2,298$2,333$2,312$2,422
Operating Income-$62$47$269$338$483$500
Non-Operating
Net Interest Expense$35$47$33$52$20$17
Other Non-Operating Income (Expense)$1,347$902-$2,645-$1,239-$5,207$4,931
EBT (Earnings Before Tax)$1,320$996-$2,343-$850-$4,704$5,449
Income Tax Expense$297$236-$498-$213-$1,077$1,195
Net Income
Net Income$1,023$760-$1,844-$637-$3,628$4,254
Per Share Data
Revenue Per Share$96.17$94.64$90.97$91.45$93.83$96.75
EPS (Basic)$38.08$27.87-$65.36-$21.82-$121.79$142.61
EPS (Diluted)$37.91$27.85-$65.36-$21.82-$121.79$140.83
Weighted Avg Shares (Basic)26.8M27.3M28.2M29.2M29.8M29.8M
Weighted Avg Shares (Diluted)26.9M27.3M28.2M29.2M29.8M30.2M
Shares Outstanding26.9M27.3M28.2M29.2M29.8M30.2M

Bio-Rad Laboratories (BIO) financials: revenue, profit and margins

Bio-Rad Laboratories (BIO) generated about $2.6 billion in revenue and $222 million in net income (a 8.6% net margin) over the trailing twelve months, growing at roughly 0.3% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Bio-Rad Laboratories's (BIO) revenue?+

Bio-Rad Laboratories generated about $2.6 billion in revenue over the trailing twelve months. Revenue has grown at roughly 0.3% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Bio-Rad Laboratories profitable?+

Yes, Bio-Rad Laboratories reported about $222 million in net income over the trailing twelve months, a net profit margin of roughly 8.6%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Bio-Rad Laboratories's profit margins?+

Bio-Rad Laboratories runs a gross margin of about 51.9%, an operating margin of about 2.1%, a net margin of about 8.6%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Bio-Rad Laboratories growing?+

Bio-Rad Laboratories's revenue has compounded at roughly 0.3% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside BIO's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 5 Aug 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Laboratory Analytical Instruments · Pick stocks to compare with BIO

CompareIntrinsic value
RVTYRevvity Inc.
$159.44-2.47%20
BRKRBruker Corporation
$63.79+12.90%23
WATWaters Corporation
$467.60+1.67%25
MTDMettler-Toledo International Inc.
$1,723.24+1.48%41
ILMNIllumina, Inc.
$226.54-4.90%68
TXG10x Genomics Inc.
$67.52+3.42%48
AVTRAvantor Inc.
$15.65+0.38%22
AAgilent Technologies Inc.
$177.17+0.97%44

Held by ETFs

BIO is in 117 US ETFs. The largest of them, with BIO's weight in each:

Spot a number that looks wrong? Check it in BIO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BIO

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.